Revance Therapeutics, Inc. (RVNC)
收市後：
| 前收市價 | 3.4000 |
| 開市 | 3.4500 |
| 買盤 | 3.6700 x 800 |
| 賣出價 | 3.7000 x 400 |
| 今日波幅 | 3.4100 - 3.7700 |
| 52 週波幅 | 3.2100 - 37.9800 |
| 成交量 | |
| 平均成交量 | 1,867,375 |
| 市值 | 384.557M |
| Beta 值 (5 年，每月) | 1.09 |
| 市盈率 (最近 12 個月) | 無 |
| 每股盈利 (最近 12 個月) | -3.8300 |
| 業績公佈日 | 2024年5月06日 - 2024年5月21日 |
| 遠期股息及收益率 | 無 (無) |
| 除息日 | 無 |
| 1 年預測目標價 | 14.91 |
Insider MonkeyRevance Therapeutics, Inc. (NASDAQ:RVNC) Q4 2023 Earnings Call Transcript
Revance Therapeutics, Inc. (NASDAQ:RVNC) Q4 2023 Earnings Call Transcript February 29, 2024 Revance Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Welcome to the Revance Therapeutics Fourth Quarter and Full Year 2023 Financial Results and Corporate Update Conference […]
ZacksHalozyme Therapeutics (HALO) Q4 Earnings Match Estimates
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 0% and 2.22%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
- Insider Monkey
Revance Therapeutics, Inc. (NASDAQ:RVNC) Q3 2023 Earnings Call Transcript
Revance Therapeutics, Inc. (NASDAQ:RVNC) Q3 2023 Earnings Call Transcript November 8, 2023 Revance Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-1.63 EPS, expectations were $-1.1. Operator: Welcome to the Revance Therapeutics Third Quarter 2023 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode. Following management’s […]
